ArticleLancet regional health. Americas2026
Targeted termination of scientific grants and minoritised researcher status in a national survey: a cross sectional analysis.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Between January and May 2025, the National Institutes of Health terminated over 2000 grants primarily relating to health equity, particularly for Black, Indigenous, and people of color (BIPOC) and sexual and gender minority (SGM) communities. 600 grants were terminated as part of blanket, institution-wide actions that were purportedly to "combat anti-Semitism." Methods: N = 1918 investigators with grant terminations documented in the Grant Witness database were sent a unique link for an online demographic survey. We built logistic regression models to assess the odds of receiving different grant termination types, for BIPOC, SGM, female, and Jewish researchers. Findings: 941 investigators participated (49.1% response rate). Nearly half (48.6%) of investigators with equity-related terminations were BIPOC and 60.0% of investigators with gender-related terminations were SGM, including 16.5% who identified as transgender or non-binary. Additionally, 20.5% of investigators with institutional terminations (for purported antisemitism) were Jewish. Among investigators of terminated grants, BIPOC investigators had higher odds of receiving an equity-related termination (aOR = 2.69, 95% CI: 1.71-4.25 for BIPOC women and trans/nonbinary investigators, aOR = 1.82, 95% CI: 1.10-3.02 for BIPOC men) compared to White men. SGM investigators had 11 times higher odds of receiving a gender-related termination (aOR = 11.14, 95% CI: 6.85-18.12) than heterosexual, cisgender investigators, and White women and trans/non-binary investigators had double the odds (aOR = 2.24, 95% CI: 1.25-4.02) of a gender-related termination than cisgender White men. Interpretation: Grant terminations targeting health research for BIPOC and SGM communities have disproportionately targeted the careers of BIPOC, SGM, and female researchers and researchers from disadvantaged backgrounds. Ensuring the health of all Americans will require systematic re-investment in these topics and scientists. Funding: The authors received no external funding for this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.